Depatuxizumab
Based on 1 Customer Validation
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer.
For research use only. We do not sell to patients.
- Purity: 99.58%
- CAS No.: 1471999-69-5
- Molecular Weight:144.54 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All EGFR Isoforms
More
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
ERBB1/EGFR/HER1
In Vivo
Depatuxizumab (10, 40 mg/kg, i.p., three times a week for 2 weeks) inhibits tumor growth and pEGFR levels in EGFRvIII-positive GBM SN0199 PDX models of NSG mice[1].
Depatuxizumab (2-40 mg/kg, i.p., three times a week for 2 weeks) inhibits tumor growth with dose dependent manner in SCC15 xenograft models of SCID Beige mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:U87MGde2-7 glioblastoma multiforme (GBM) model of Nu/Nu mice[1]
-
Dosage:10, 40 mg/kg, three times a week for 2 weeks
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Inhibited tumor growth significantly more than Cetuximab (HY-P9905).
Promoted a significant increase in TGI (tumor growth inhibition) when it combined with Temozolomide (HY-17364).
-
Animal Model:EGFRvIII-positive GBM SN0199 PDX model, 3 to 5 mm3 passage 3 (P3) tumor fragments were s.c. trochar implanted in the right rear flank of NSG mice[1]
-
Dosage:10, 40 mg/kg, three times a week for 2 weeks
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Inhibited tumor growth significantly and reduced levels of pEGFR.
-
Animal Model:A431 squamous xenograft model of Nu/Nu mice[1]
-
Dosage:10, 40 mg/kg, three times a week for 2 weeks
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Inhibited tumor growth with comparable activity to Cetuximab (HY-P9905) dosed in an equivalent manner at 10 mg/kg.
Inhibited tumor growth by 58% at 40 mg/kg.
-
Animal Model:SCC15 xenograft model of SCID Beige mice[1]
-
Dosage:2, 10, 20, 40 mg/kg, three times a week for 2 weeks
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Inhibited tumor growth with dose manner.
Reduced the level of pEGFR and total EGFR in time-dependent.
Reduced cell proliferation as measured by phospho-histone H3.
Increased apoptosis as measured by caspase-3 cleavage.
Increased antitumor activity when it was combined with both Cisplatin(HY-17394) or/and 5-FU(HY-90006) at 10 mg/kg.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized EGFR Protein, Human can bind Depatuxizumab. The EC50 for this effect is 52.87 ng/mL. -
Flow Cytometry analysis of A431 cells labelling ERBB1/EGFR/HER1 (red) with Depatuxizumab (anti-ERBB1/EGFR/HER1) (HY-P99849). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 1471999-69-5
-
Appearance Liquid
-
Molecular Weight 144.54 kDa
-
Color Colorless to light yellow
-
SMILES
[Depatuxizumab]
-
Synonyms
ABT-806
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Depatuxizumab Related Classifications
HY-P99849 Related Classifications
Powered by Bioz